The Discovery of the Body's Own Cannabis-Like Molecules: Anandamide and 2-AG
A landmark review by the discoverers of the endocannabinoid system described the isolation, structure, synthesis, and function of anandamide and 2-arachidonoyl glycerol, the body's own cannabis-like molecules.
Quick Facts
What This Study Found
This review, authored by Raphael Mechoulam and colleagues who played central roles in discovering the endocannabinoid system, described two molecules the body produces naturally that activate the same receptors as THC.
Anandamide and 2-arachidonoyl glycerol (2-AG) were identified as the principal endocannabinoids. The review covered their chemical structures, how structural modifications affect their activity, their levels in unstimulated tissues and cells, and how the body makes, releases, and breaks them down.
A key concept introduced was the "entourage effect": companion compounds that do not directly activate cannabinoid receptors but modify the activity of anandamide and 2-AG, potentially amplifying or modifying their effects. The review also described their signaling mechanisms within cells and their effects when administered to animals.
Key Numbers
Two principal endocannabinoids identified: anandamide and 2-arachidonoyl glycerol (2-AG). The entourage effect concept was introduced.
How They Did This
Comprehensive review by key researchers in the field, covering endocannabinoid discovery, structure-activity relationships, biochemistry (biosynthesis, release, inactivation), the entourage effect, signaling mechanisms, and animal pharmacology.
Why This Research Matters
This review documented one of the most significant biological discoveries of the 1990s. The finding that humans have an endogenous cannabinoid system reframed the entire field: cannabis was not introducing foreign chemistry but rather hijacking a natural signaling system. This transformed both therapeutic research and our understanding of brain function.
The Bigger Picture
The endocannabinoid system is now recognized as one of the most widespread neuromodulatory systems in the body, involved in pain, mood, appetite, sleep, immune function, and more. The "entourage effect" concept has become central to debates about whole-plant cannabis versus single-molecule therapeutics.
What This Study Doesn't Tell Us
The field was young and many details were still being worked out. Some conclusions from this era were later refined or revised. The clinical significance of endocannabinoid biology was still largely theoretical.
Questions This Raises
- ?What role does endocannabinoid signaling play in specific disease states?
- ?Can the entourage effect be harnessed therapeutically?
- ?How does chronic cannabis use affect the endocannabinoid system?
Trust & Context
- Key Stat:
- Two endocannabinoids identified: anandamide and 2-AG, with "entourage" companions
- Evidence Grade:
- A comprehensive review by the field's principal discoverers. Authoritative firsthand account of a major biological discovery.
- Study Age:
- Published in 1998, during the early characterization of the endocannabinoid system. The field has expanded enormously, with thousands of subsequent studies.
- Original Title:
- Endocannabinoids.
- Published In:
- European journal of pharmacology, 359(1), 1-18 (1998)
- Authors:
- Mechoulam, R(10), Fride, E, Di Marzo, V(3)
- Database ID:
- RTHC-00072
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does the body make its own cannabis?
Yes. The body produces anandamide and 2-AG, which activate the same receptors as THC. These are called endocannabinoids and are part of a natural signaling system.
What is the entourage effect?
Companion molecules that don't directly activate cannabinoid receptors but modify the activity of endocannabinoids, potentially enhancing or changing their effects. This concept has become important in understanding whole-plant cannabis.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00072APA
Mechoulam, R; Fride, E; Di Marzo, V. (1998). Endocannabinoids.. European journal of pharmacology, 359(1), 1-18.
MLA
Mechoulam, R, et al. "Endocannabinoids.." European journal of pharmacology, 1998.
RethinkTHC
RethinkTHC Research Database. "Endocannabinoids." RTHC-00072. Retrieved from https://rethinkthc.com/research/mechoulam-1998-endocannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.